CN-122005590-A - Medicine for treating gouty arthritis and preparation method thereof

Abstract

The invention discloses a medicine for treating gouty arthritis and a preparation method thereof, and belongs to the technical field of medicines. The invention mainly comprises homoplantagin and cornus officinalis neoside, wherein the weight ratio of the homoplantagin to the cornus officinalis neoside is 13:7, the optimal effective total dose of the medicine is 128mg/kg, and the homoplantagin and the cornus officinalis neoside are taken as core active ingredients and are in accurate weight ratio, and the homoplantagin and the cornus officinalis neoside are synergistic, so that inflammatory cascade reaction of gouty arthritis can be blocked, surface symptoms can be relieved simply, and disease repetition can be effectively reduced.

Inventors

• LI WENHAO
• LI XUE
• REN PENGPENG
• JIANG DEYOU
• JIANG LING
• LI JIAMENG
• Huo Xuanming
• XU ZHIBO
• ZHAO YAPENG
• SHEN YIWEI

Assignees

• 黑龙江中医药大学

Dates

Publication Date

20260512

Application Date

20260401

Claims (4)

1. 1. A medicine for treating gouty arthritis is characterized by comprising homoplantain and cornus officinalis neoside, wherein the weight ratio of the homoplantain to the cornus officinalis neoside is 13:7, the optimal effective total dose of the medicine is 128mg/kg, the raw materials for preparing the medicine are subjected to drying pretreatment until the water content is less than 9%, the drying pretreatment adopts a vacuum low-temperature drying mode, the drying temperature is controlled to be 30-40 ℃, and the drying time is 2-4h.
2. 2. The medicine for treating gouty arthritis according to claim 1, wherein the medicine can be prepared into tablets, pills, powder, hard capsules, soft capsules, granules and oral liquid.
3. 3. The medicine for treating gouty arthritis according to claim 1, wherein the medicine further comprises pharmaceutically acceptable pharmaceutical excipients, and the pharmaceutical excipients are selected from starch and lactose.
4. 4. A method for preparing a medicament for treating gouty arthritis, which is used for preparing the medicament according to any one of claims 1 to 3, and is characterized by comprising the following steps: S1, carrying out drying pretreatment on a homoplantagin and cornus officinalis neoglycoside raw material until the water content is less than 9%, wherein the drying pretreatment adopts a vacuum low-temperature drying mode, the drying temperature is controlled to be 30-40 ℃, and the drying time is 2-4 hours; then precisely weighing 13 parts by weight of pretreated homoplantagin and 7 parts by weight of pretreated cornus officinalis neoside in a hundred-level cleanliness weighing chamber by adopting a ten-thousandth precision electronic analytical balance; the environmental parameters of the hundred-grade cleanliness weighing chamber are that the temperature is 20-25 ℃ and the relative humidity is 45-65%; S2, placing the homoplantagin and the cornus officinalis neoglycoside weighed in the S1 into a three-dimensional motion mixer with hundred-level cleanliness, adjusting the rotating speed of the mixer to 10-15r/min, and mixing for 15-20min; S3, adding pharmaceutically acceptable pharmaceutic adjuvants into the mixture of the homoplantagin and the cornus officinalis neoside which are uniformly mixed in the S2, wherein the pharmaceutic adjuvants are required to be added in a sterile operation environment, and the pharmaceutic adjuvants are required to be dried and sterilized before being added, and the water content of the pharmaceutic adjuvants is controlled to be less than or equal to 8%; S4, processing the medicine mixture obtained in the S3 into a target dosage form according to a conventional pharmaceutical process of a pharmaceutical general standard, and obtaining a finished medicine product.

Description

Medicine for treating gouty arthritis and preparation method thereof Technical Field The invention relates to the technical field of medicines, in particular to a medicine for treating gouty arthritis and a preparation method thereof. Background Gouty arthritis (gouty arthritis) is an acute inflammatory response triggered by the deposition of monosodium urate (monosodium urate, MSU) crystals on the joint synovium, and clinically manifested by sudden redness, swelling, fever and pain, limited movement. The core pathological mechanism is that MSU crystals activate inflammatory cells such as macrophages and neutrophils, inflammatory factors such as IL-1 beta, IL-6, TNF-alpha and the like are triggered to release to form cascade reaction, and finally, joint redness, severe pain and dysfunction are caused, joint deformity and renal function injury can be caused when the joint redness, the severe pain and the dysfunction are serious, and the life quality of patients is obviously reduced. With the increase of the westernization of the global diet structure, the increase of the obesity rate and the aging of the population, the incidence rate of gouty arthritis is continuously increased, and the onset population shows a younger trend, so the gouty arthritis has become a common disease which seriously affects public health. At present, clinical treatment aims at controlling acute inflammation and reducing blood uric acid level, and common medicaments comprise colchicine, non-steroidal anti-inflammatory drugs, glucocorticoid and the like. Colchicine is used as a classical medicine for treating acute gouty arthritis, which can quickly inhibit inflammatory reaction, but has narrow treatment window, and long-term or excessive use of colchicine is easy to cause adverse reactions such as gastrointestinal discomfort, bone marrow suppression, liver and kidney function injury and the like, and non-steroidal anti-inflammatory drugs can cause problems such as gastrointestinal bleeding, increased cardiovascular risk and the like, and part of patients cannot use the colchicine because of drug allergy or poor tolerance. In addition, the existing medicines are focused on relieving symptoms, so that the balance of inflammatory pathways is difficult to fundamentally regulate, the illness state of part of patients is easy to repeat, and the development of novel therapeutic medicines with definite curative effect, high safety and comprehensive action mechanism is needed in clinic. Gaoguansu (Hispidulin) is a flavonoid compound with various pharmacological activities such as anti-inflammatory, antioxidant, antitumor and neuroprotection, and the chemical name of the flavonoid compound is 4',5, 7-trihydroxy-6-methoxy flavone, and the molecular formula of the flavonoid compound is C16H12O6. The homoplantain also exists in other traditional Chinese herbal medicines, such as common sage herb, saussurea involucrata and the like, and has multiple pharmacological effects of anti-inflammatory, antioxidant, anti-tumor, liver protection and the like. Cornuside (Cornuside) is an iridoid glycoside compound isolated from dried pulp of cornaceae plants and has the chemical name methyl (2 r,3s,4 r) -3-vinyl-4- [2- (3, 4, 5-trihydroxybenzoyl) oxyethyl ] -2- [ (2 s,3r,4s,5s,6 r) -3,4, 5-trihydroxy-6-hydroxymethyl oxetan-2-yl ] oxy-3, 4-dihydro-2H-pyran-5-carboxylate with molecular formula of C34H50O20. Has effects in inhibiting inflammatory reaction, reducing blood glucose level, improving vascular endothelial cell function, and protecting myocardial injury. Although homoplantagin and cornus officinalis neoglycoside are reported to have certain anti-inflammatory activity, in the field of gouty arthritis treatment, the single application often cannot achieve ideal curative effect due to single action target point, insufficient efficacy strength and other reasons, and the related research of the combined application of homoplantagin and cornus officinalis neoglycoside, especially the key scientific problems of synergy, optimal compatibility proportion, effective dosage range and the like, are insufficient at present. Based on the traditional theory of traditional Chinese medicine 'compatibility and synergy' and the modern medicine combination strategy, the two natural active ingredients with different action mechanisms are scientifically compatible, so that the effects are expected to be realized, the anti-inflammatory, analgesic and joint protection effects are obviously enhanced, and meanwhile, the combination strategy can also reduce the dosage of a single ingredient and effectively reduce potential adverse reactions. The patent document with the authority of CN104873624B in the prior art discloses a medicine composition for gouty arthritis, which comprises 10-50 parts of glabrous sarcandra herb, 10-30 parts of polygonum multiflorum, 15-40 parts of polygonum cuspidatum, 8-25 parts of schisandra chinensis, 10-40 parts of iron-horse penis, 5-25 parts of r